Premium
Treatment of anorexia and weight loss with megestrol acetate in patients with cystic fibrosis
Author(s) -
Nasr Samya Z.,
Hurwitz Martin E.,
Brown Randall W.,
Elghoroury Mahmoud,
Rosen David
Publication year - 1999
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/(sici)1099-0496(199911)28:5<380::aid-ppul11>3.0.co;2-a
Subject(s) - megestrol acetate , medicine , appetite , anorexia , weight loss , megestrol , cystic fibrosis , weight gain , gastroenterology , body weight , pediatrics , obesity , cancer
Four patients with severe cystic fibrosis lung disease, anorexia and weight loss, received Megestrol Acetate (MA), as an appetite stimulant. The initial dose was 400–800 mg daily and was continued for 6–15 months. Appetite was improved, with significant weight gain in all patients and an increase in their weight for age percentile from <5% at the start of the study to approximately the 25 th percentile after 6 months of use and improvement in quality of life. One patient discontinued MA after 6 months, and subsequently appetite and weight were depressed. Pediatr Pulmonol. 1999; 28:380–382. © 1999 Wiley‐Liss, Inc.